Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.14
NYSE:ZTS's Cash-to-Debt is ranked lower than
88% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. NYSE:ZTS: 0.14 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:ZTS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.16 Max: N/A
Current: 0.14
Equity-to-Asset 0.21
NYSE:ZTS's Equity-to-Asset is ranked lower than
93% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NYSE:ZTS: 0.21 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:ZTS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.19 Max: 0.69
Current: 0.21
0.12
0.69
Interest Coverage 8.64
NYSE:ZTS's Interest Coverage is ranked lower than
74% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. NYSE:ZTS: 8.64 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:ZTS' s Interest Coverage Range Over the Past 10 Years
Min: 2.3  Med: 8.42 Max: 22.42
Current: 8.64
2.3
22.42
Piotroski F-Score: 6
Altman Z-Score: 4.91
Beneish M-Score: -2.36
WACC vs ROIC
8.65%
18.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 28.59
NYSE:ZTS's Operating Margin % is ranked higher than
92% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. NYSE:ZTS: 28.59 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:ZTS' s Operating Margin % Range Over the Past 10 Years
Min: -4.53  Med: 16.72 Max: 28.59
Current: 28.59
-4.53
28.59
Net Margin % 17.25
NYSE:ZTS's Net Margin % is ranked higher than
81% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. NYSE:ZTS: 17.25 )
Ranked among companies with meaningful Net Margin % only.
NYSE:ZTS' s Net Margin % Range Over the Past 10 Years
Min: -3.62  Med: 8.59 Max: 17.25
Current: 17.25
-3.62
17.25
ROE % 59.35
NYSE:ZTS's ROE % is ranked higher than
97% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. NYSE:ZTS: 59.35 )
Ranked among companies with meaningful ROE % only.
NYSE:ZTS' s ROE % Range Over the Past 10 Years
Min: 11.26  Med: 24.4 Max: 64.27
Current: 59.35
11.26
64.27
ROA % 11.25
NYSE:ZTS's ROA % is ranked higher than
81% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. NYSE:ZTS: 11.25 )
Ranked among companies with meaningful ROA % only.
NYSE:ZTS' s ROA % Range Over the Past 10 Years
Min: 4.68  Med: 8.22 Max: 11.25
Current: 11.25
4.68
11.25
ROC (Joel Greenblatt) % 46.91
NYSE:ZTS's ROC (Joel Greenblatt) % is ranked higher than
82% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.97 vs. NYSE:ZTS: 46.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:ZTS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.65  Med: 32.08 Max: 50.38
Current: 46.91
24.65
50.38
3-Year Revenue Growth Rate 2.50
NYSE:ZTS's 3-Year Revenue Growth Rate is ranked lower than
60% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. NYSE:ZTS: 2.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:ZTS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.1 Max: 8.4
Current: 2.5
0
8.4
3-Year EBITDA Growth Rate 17.50
NYSE:ZTS's 3-Year EBITDA Growth Rate is ranked higher than
67% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. NYSE:ZTS: 17.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:ZTS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 17.5 Max: 36.2
Current: 17.5
0
36.2
3-Year EPS without NRI Growth Rate 17.80
NYSE:ZTS's 3-Year EPS without NRI Growth Rate is ranked higher than
67% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. NYSE:ZTS: 17.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:ZTS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 17.8 Max: 66.2
Current: 17.8
0
66.2
GuruFocus has detected 4 Warning Signs with Zoetis Inc $NYSE:ZTS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:ZTS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:TEVA, OTCPK:TKPYY, NAS:MYL, OTCPK:SGIOY, OTCPK:ESALY, OTCPK:MKGAY, OTCPK:MTZPY, OTCPK:IPSEY, OTCPK:HLUYY, NYSE:PRGO, OTCPK:APNHY, NYSE:RDY, OTCPK:GZPHY, OTCPK:HYPMY, NYSE:PTHN, OTCPK:HKMPF, OTCPK:RGEDF, NYSE:CTLT, NYSE:TARO, NYSE:VRX » details
Traded in other countries:ZOE.Germany,
Headquarter Location:USA
Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products.

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns the majority of its revenue from production animals (cattle, pigs, poultry, and so on) but also sells companion animal (dogs, horses, cats) products. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Guru Investment Theses on Zoetis Inc

Bill Ackman Comments on Zoetis - May 08, 2017

On November 9, 2016, we sold our last shares of Zoetis (NYSE:ZTS), about two years after we publicly announced an 8.5% ownership stake. Despite the high quality nature of the business and its strong management team, we sold to redeploy the capital in certain new investments.

We purchased our stake in Zoetis at an average cost of approximately $37 per share. Shortly thereafter, we met with the Zoetis management to discuss our views on potential initiatives to create shareholder value. On February 4, 2015, Zoetis agreed to add then-Pershing Square investment team member (and healthcare industry veteran) Bill Doyle and Actavis Executive Chairman Paul Bisaro to the board on April 13, 2015.

Over the course of our ownership, ZTS developed and implemented a number of value-enhancing initiatives including restructuring its supply chain, pursuing organic revenue growth opportunities while reducing costs, and setting a goal of increasing operating margins from ~25% in 2014 to ~34% by 2017. Zoetis outperformed each of these objectives during our ownership.

During our more than two-year ownership, Zoetis generated a total shareholder return, including dividends, of 57.9%.

From 2016 annual letter to shareholders of Pershing Square by Bill Ackman (Trades, Portfolio).

Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis - Mar 30, 2017



On November 9, 2016, we sold our last shares of Zoetis (NYSE:ZTS), about two years after we publicly announced an 8.5% ownership stake. Despite the high quality nature of the business and its strong management team, we sold to redeploy the capital in certain new investments.

We purchased our stake in Zoetis at an average cost of approximately $37 per share. Shortly thereafter, we met with the Zoetis management to discuss our views on potential initiatives to create shareholder value. On February 4, 2015, Zoetis agreed to add then-Pershing Square investment team member (and healthcare industry veteran) Bill Doyle and Actavis Executive Chairman Paul Bisaro to the board on April 13, 2015.

Over the course of our ownership, ZTS developed and implemented a number of value-enhancing initiatives including restructuring its supply chain, pursuing organic revenue growth opportunities while reducing costs, and setting a goal of increasing operating margins from ~25% in 2014 to ~34% by 2017. Zoetis outperformed each of these objectives during our ownership.

During our more than two-year ownership, Zoetis generated a total shareholder return, including dividends, of 57.9%.

From Bill Ackman (Trades, Portfolio)'s Pershing Square 2016 annual report.


Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis - Dec 09, 2016

On November 9th we sold our last shares of Zoetis (NYSE:ZTS), about two years after we publicly announced an 8.5% ownership stake. Despite the high quality nature of the business and its strong management team, we sold to redeploy the capital in certain new investments.

We purchased our stake in Zoetis at an average cost of approximately $37 per share. Shortly thereafter, we met with the Zoetis management to learn more about the company and to discuss our views on potential initiatives to create shareholder value. On February 4, 2015, Zoetis agreed to add then-Pershing Square investment team member (and healthcare industry veteran) Bill Doyle and Actavis Executive Chairman Paul Bisaro to the board on April 13, 2015.

Over the course of our ownership, ZTS developed and implemented a number of value-enhancing initiatives including restructuring its supply chain, pursuing organic revenue growth opportunities while reducing costs, and setting a goal of increasing operating margins from ~25% in 2014 to ~34% by 2017. Zoetis outperformed each of these objectives during our ownership.

We sold our remaining shares of Zoetis on November 9th. During our more than two-year ownership, Zoetis generated a total shareholder return of 58%.

From Bill Ackman (Trades, Portfolio)'s Pershing Square third-quarter shareholder letter.

Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis Inc. - Aug 29, 2016

There is still a lot more work to do, but we are pleased with the company's progress over the last several months. Zoetis Inc. (NYSE:ZTS) Zoetis delivered another exceptional quarter of performance. Organic revenue growth was +4%, driven by +13% growth in Zoetis' companion animal segment. Excluding the revenue impact of the company's operational efficiency initiatives, organic revenue growth was 9%. Management's execution of its operational efficiency initiative continues to be excellent. SG&A as a percentage of sales fell by 180bps in the quarter, year-over-year and gross margins expanded 240bps. While we have sold a substantial portion of our investment to raise capital for new investments, we continue to believe that Zoetis' history of strong organic growth and margin expansion will continue.

From Bill Ackman (Trades, Portfolio)'s mid-year 2016 letter.

Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis Inc. - May 11, 2016

Zoetis (NYSE:ZTS) is the only large, independent, publicly traded animal health company in the world. The company has a market capitalization of ~$23 billion and $5 billion in revenue. The Pershing Square funds currently own a 5.0% economic stake in the company, down from 8.6% as a result of a recent block sale.

During the first quarter, adjusted revenue grew 6%. The Companion Animal segment was the star of the quarter, with growth of 20% driven by new product launches. Livestock revenue growth was nominal at 1% due to competition in U.S. swine products and mild U.S. weather.

Gross margins and SG&A spending were both better than expectations. Management continues to execute well on the cost efficiency program announced in May 2015. SG&A fell by 6% YoY, despite six extra days in the quarter. Operating margins expanded ~500 bps from the prior year. Management now believes savings from the efficiency program will exceed the original $300 million targeted when the program was announced last May. All savings from this program are expected to be realized by 2017.

Good performance and favourable FX allowed management to increase earnings guidance by $0.10/share in 2016 and $0.06/share in 2017.

We executed a block sale of 16.85 million shares on May 9th, reducing our ownership of the company from 8.6% to 5.0%. We continue to be pleased with management’s performance and have high expectations for the company. As with CP and Mondelez, we reduced our position for portfolio management reasons.

Bill Doyle, who has represented Pershing Square on the ZTS board since February 4, 2015, will not stand for re-election at the annual meeting on May 12th. We no longer feel that our presence on the board is required as the company continues to generate strong progress as evidenced by first quarter results.

From Bill Ackman (Trades, Portfolio)'s first quarter shareholder letter.

Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis Inc. - Dec 16, 2015

Zoetis, Inc. (NYSE:ZTS)

On November 3rd, Zoetis reported another strong quarter. Operational revenue grew 9% and operational adjusted net income grew 31%, excluding the impact of foreign exchange. Growth was driven by strong performance in the U.S. livestock business, the integration of the Abbott Animal Health business that was acquired in the first quarter of 2015, and growth in recently launched products in the companion animal sector. Reported revenue of $1.2 billion was flat year-on-year, while reported EPS of $0.38 represented a 15% increase over third quarter 2014 reported EPS.

Adjusted diluted net income per share, which excludes purchase accounting adjustments and certain one-time costs, was $0.50. This is an increase of 22% compared to third quarter 2014, and significantly in excess of the Wall Street consensus adjusted EPS estimate of $0.40 per share.

Management continues to demonstrate its expense discipline. Operating expenses grew 3% while operational revenue grew 9% excluding the impact of foreign exchange. Management reaffirmed its commitment to meet or exceed the previously announced $300 million expense reduction target by 2017.

During the quarter, the company announced the $765 million acquisition of PHARMAQ, the global leader in vaccines for aquaculture, or farmed fish. Aquaculture is the fastest growing segment of the global animal health industry and is the only segment in which Zoetis had limited presence. The PHARMAQ acquisition provides a market-leading portfolio of vaccines and pharmaceuticals for farmed fish as well as a late-stage development pipeline anticipated to deliver important new vaccines and next-generation parasiticides in the near term. PHARMAQ is a good strategic fit with Zoetis, and provides another pillar for long-term growth. The company believes this acquisition will enjoy a long period of sustainable growth in revenue, profits, and cash flow when added into its business.

From Bill Ackman (Trades, Portfolio)'s Pershing Square Holdings third quarter 2015 letter to shareholders.

Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis Inc. - Sep 11, 2015

Zoetis, Inc. (NYSE:ZTS)



Second quarter earnings exceeded analyst expectations. Management raised 2015 earnings guidance modestly for the year. Revenue growth in the quarter was impressive. Organic revenue adjusted for foreign exchange was 9%. Approximately 80% of revenue growth in the quarter is attributable to volume growth of recently launched and existing products. Operating expenses, adjusted for foreign exchange, rose only 1%, despite an 11% increase in revenue. Management announced significant progress in its R&D portfolio, including advances in new product innovation and improvements to existing products.



In May, Zoetis announced a large cost restructuring program. Management has begun to take its first steps towards achieving this plan and believes it is on track to deliver its target of at least $300 million of savings, which will increase Zoetis’ operating profit margin from 25% in 2014 to 34% in 2017 according to the company’s second quarter conference call. Thereafter, management expects a combination of continued cost discipline, strong revenue growth, and execution of management’s supply chain efficiency program will result in continuing improvements in operating profit margins.



From Pershing Square's semi-annual 2015 report.



Check out Bill Ackman latest stock trades

Top Ranked Articles about Zoetis Inc

Bill Ackman Comments on Zoetis Guru stock highlight
On November 9, 2016, we sold our last shares of Zoetis (NYSE:ZTS), about two years after we publicly announced an 8.5% ownership stake. Despite the high quality nature of the business and its strong management team, we sold to redeploy the capital in certain new investments. Read more...
Bill Ackman Comments on Zoetis Guru stock highlight
On November 9, 2016, we sold our last shares of Zoetis (NYSE:ZTS), about two years after we publicly announced an 8.5% ownership stake. Despite the high quality nature of the business and its strong management team, we sold to redeploy the capital in certain new investments.

We purchased our stake in Zoetis at an average cost of approximately $37 per share. Shortly thereafter, we met with the Zoetis management to discuss our views on potential initiatives to create shareholder value. On February 4, 2015, Zoetis agreed to add then-Pershing Square investment team member (and healthcare industry veteran) Bill Doyle and Actavis Executive Chairman Paul Bisaro to the board on April 13, 2015.

Over the course of our ownership, ZTS developed and implemented a number of value-enhancing initiatives including restructuring its supply chain, pursuing organic revenue growth opportunities while reducing costs, and setting a goal of increasing operating margins from ~25% in 2014 to ~34% by 2017. Zoetis outperformed each of these objectives during our ownership.

During our more than two-year ownership, Zoetis generated a total shareholder return, including dividends, of 57.9%.

From Bill Ackman (Trades, Portfolio)'s Pershing Square 2016 annual report. Read more...
Bill Ackman Expands Chipotle Position, Cuts Zoetis Activist investor trims 3 positions in 4th quarter
Activist investor Bill Ackman (Trades, Portfolio), founder of Pershing Square Capital Management, buys the common stock of companies and pushes for changes so that the market can realize the values of these companies. Like fellow activist investor Carl Icahn (Trades, Portfolio), Ackman buys out-of-favor companies at a discount and sells them when the companies reach their appraised value. Read more...
Manning & Napier’s Top 3 New Holdings Firm invested in wide array of industries in the 4th quarter
Manning & Napier Advisors Inc. acquired 35 new holdings during the final quarter of 2016. The firm’s top three new holdings are Bristol-Myers Squibb Co. (NYSE:BMY), Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Campbell Soup Co. (NYSE:CPB). Read more...
Bill Ackman Comments on Zoetis Guru stock highlight
On November 9th we sold our last shares of Zoetis (NYSE:ZTS), about two years after we publicly announced an 8.5% ownership stake. Despite the high quality nature of the business and its strong management team, we sold to redeploy the capital in certain new investments. Read more...
Bill Ackman Comments on Zoetis Inc. Guru stock highlight
There is still a lot more work to do, but we are pleased with the company's progress over the last several months. Zoetis Inc. (NYSE:ZTS) Zoetis delivered another exceptional quarter of performance. Organic revenue growth was +4%, driven by +13% growth in Zoetis' companion animal segment. Excluding the revenue impact of the company's operational efficiency initiatives, organic revenue growth was 9%. Management's execution of its operational efficiency initiative continues to be excellent. SG&A as a percentage of sales fell by 180bps in the quarter, year-over-year and gross margins expanded 240bps. While we have sold a substantial portion of our investment to raise capital for new investments, we continue to believe that Zoetis' history of strong organic growth and margin expansion will continue. Read more...
Ackman Raises $1.4 Billion Selling Entire Stake in Canadian Pacific Railway Close of stake comes on wave of sells by Pershing
Bill Ackman (Trades, Portfolio) is selling off 14 million shares of Canadian Pacific Railway Ltd. (NYSE:CP)(TSX:CP) – a stock making up about a fifth of his equity portfolio – ending one of his big turnaround plays. Read more...
Bill Ackman’s Portfolio Returns Diminish as Stock Prices Decline An introduction to the activist investor and his portfolio, conference call is scheduled for tomorrow
Activist investor Bill Ackman (Trades, Portfolio) founded the Pershing Square Capital Management Fund in 2003. With a simple investing approach, the fund manager seeks value by buying stocks at cheap prices and selling them once they reach their fair values. Despite having high returns in 2014, the fund experienced poor returns as of July 2016. Read more...
Ackman Sells Nearly a Quarter of Stake in Zoetis Guru trims position by more than 6 million shares
Bill Ackman (Trades, Portfolio) of Pershing Square Capital Management LP reduced his stake in Zoetis Inc. (NYSE:ZTS) for the second time this year with the sale of 6,081,841 shares for $47.69 per share on July 7. Read more...

Ratios

vs
industry
vs
history
PE Ratio 36.92
ZTS's PE Ratio is ranked lower than
65% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.12 vs. ZTS: 36.92 )
Ranked among companies with meaningful PE Ratio only.
ZTS' s PE Ratio Range Over the Past 10 Years
Min: 27.31  Med: 36.76 Max: 69.75
Current: 36.92
27.31
69.75
Forward PE Ratio 27.17
ZTS's Forward PE Ratio is ranked lower than
71% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.73 vs. ZTS: 27.17 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 36.92
ZTS's PE Ratio without NRI is ranked lower than
65% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.32 vs. ZTS: 36.92 )
Ranked among companies with meaningful PE Ratio without NRI only.
ZTS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 27.31  Med: 36.76 Max: 69.75
Current: 36.92
27.31
69.75
Price-to-Owner-Earnings 68.29
ZTS's Price-to-Owner-Earnings is ranked lower than
78% of the 305 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.72 vs. ZTS: 68.29 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ZTS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 53.01  Med: 67.31 Max: 261.67
Current: 68.29
53.01
261.67
PB Ratio 19.40
ZTS's PB Ratio is ranked lower than
96% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. ZTS: 19.40 )
Ranked among companies with meaningful PB Ratio only.
ZTS' s PB Ratio Range Over the Past 10 Years
Min: 12.62  Med: 17.91 Max: 24.4
Current: 19.4
12.62
24.4
PS Ratio 6.37
ZTS's PS Ratio is ranked lower than
71% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. ZTS: 6.37 )
Ranked among companies with meaningful PS Ratio only.
ZTS' s PS Ratio Range Over the Past 10 Years
Min: 3.11  Med: 4.6 Max: 6.37
Current: 6.37
3.11
6.37
Price-to-Free-Cash-Flow 55.61
ZTS's Price-to-Free-Cash-Flow is ranked lower than
75% of the 210 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.65 vs. ZTS: 55.61 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ZTS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 25.69  Med: 48.99 Max: 90.56
Current: 55.61
25.69
90.56
Price-to-Operating-Cash-Flow 40.43
ZTS's Price-to-Operating-Cash-Flow is ranked lower than
79% of the 284 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.79 vs. ZTS: 40.43 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ZTS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.62  Med: 34.18 Max: 41.95
Current: 40.43
21.62
41.95
EV-to-EBIT 25.08
ZTS's EV-to-EBIT is ranked lower than
61% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.94 vs. ZTS: 25.08 )
Ranked among companies with meaningful EV-to-EBIT only.
ZTS' s EV-to-EBIT Range Over the Past 10 Years
Min: 20.2  Med: 25.5 Max: 41.6
Current: 25.08
20.2
41.6
EV-to-EBITDA 21.34
ZTS's EV-to-EBITDA is ranked lower than
61% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.60 vs. ZTS: 21.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZTS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.7  Med: 20.4 Max: 32.1
Current: 21.34
16.7
32.1
PEG Ratio 2.86
ZTS's PEG Ratio is ranked lower than
63% of the 313 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.90 vs. ZTS: 2.86 )
Ranked among companies with meaningful PEG Ratio only.
ZTS' s PEG Ratio Range Over the Past 10 Years
Min: 2.52  Med: 3.17 Max: 3.46
Current: 2.86
2.52
3.46
Current Ratio 1.96
ZTS's Current Ratio is ranked lower than
59% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. ZTS: 1.96 )
Ranked among companies with meaningful Current Ratio only.
ZTS' s Current Ratio Range Over the Past 10 Years
Min: 1.96  Med: 2.79 Max: 3.47
Current: 1.96
1.96
3.47
Quick Ratio 1.07
ZTS's Quick Ratio is ranked lower than
74% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. ZTS: 1.07 )
Ranked among companies with meaningful Quick Ratio only.
ZTS' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.54 Max: 2
Current: 1.07
1.07
2
Days Inventory 321.96
ZTS's Days Inventory is ranked lower than
94% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.03 vs. ZTS: 321.96 )
Ranked among companies with meaningful Days Inventory only.
ZTS' s Days Inventory Range Over the Past 10 Years
Min: 117.43  Med: 284.81 Max: 325.24
Current: 321.96
117.43
325.24
Days Sales Outstanding 70.25
ZTS's Days Sales Outstanding is ranked higher than
55% of the 655 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. ZTS: 70.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZTS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.18  Med: 74.93 Max: 91.07
Current: 70.25
68.18
91.07
Days Payable 49.02
ZTS's Days Payable is ranked lower than
69% of the 603 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.27 vs. ZTS: 49.02 )
Ranked among companies with meaningful Days Payable only.
ZTS' s Days Payable Range Over the Past 10 Years
Min: 47.28  Med: 61.59 Max: 110.66
Current: 49.02
47.28
110.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.65
ZTS's Dividend Yield % is ranked lower than
80% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. ZTS: 0.65 )
Ranked among companies with meaningful Dividend Yield % only.
ZTS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.21  Med: 0.71 Max: 1.08
Current: 0.65
0.21
1.08
Dividend Payout Ratio 0.23
ZTS's Dividend Payout Ratio is ranked higher than
85% of the 404 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.33 vs. ZTS: 0.23 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ZTS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.19  Med: 0.24 Max: 0.49
Current: 0.23
0.19
0.49
3-Year Dividend Growth Rate 24.90
ZTS's 3-Year Dividend Growth Rate is ranked higher than
80% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.90 vs. ZTS: 24.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ZTS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.9
Current: 24.9
0
24.9
Forward Dividend Yield % 0.67
ZTS's Forward Dividend Yield % is ranked lower than
82% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. ZTS: 0.67 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.65
ZTS's 5-Year Yield-on-Cost % is ranked lower than
82% of the 808 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.01 vs. ZTS: 0.65 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ZTS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.21  Med: 0.71 Max: 1.08
Current: 0.65
0.21
1.08
3-Year Average Share Buyback Ratio 0.50
ZTS's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. ZTS: 0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZTS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1  Med: 0 Max: 0
Current: 0.5
-0.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 5.22
ZTS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
72% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. ZTS: 5.22 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ZTS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.39  Med: 4.89 Max: 5.24
Current: 5.22
4.39
5.24
Price-to-Median-PS-Value 1.38
ZTS's Price-to-Median-PS-Value is ranked lower than
69% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. ZTS: 1.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ZTS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.69  Med: 0.98 Max: 1.38
Current: 1.38
0.69
1.38
Price-to-Peter-Lynch-Fair-Value 3.49
ZTS's Price-to-Peter-Lynch-Fair-Value is ranked lower than
81% of the 206 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ZTS: 3.49 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ZTS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 2.58  Med: 3.05 Max: 3.49
Current: 3.49
2.58
3.49
Earnings Yield (Greenblatt) % 3.99
ZTS's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.98 vs. ZTS: 3.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ZTS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.4  Med: 3.9 Max: 5
Current: 3.99
2.4
5
Forward Rate of Return (Yacktman) % 11.97
ZTS's Forward Rate of Return (Yacktman) % is ranked higher than
54% of the 381 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.09 vs. ZTS: 11.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ZTS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.8  Med: 12.2 Max: 16
Current: 11.97
11.8
16

More Statistics

Revenue (TTM) (Mil) $4,957.00
EPS (TTM) $ 1.72
Beta1.24
Short Percentage of Float2.60%
52-Week Range $45.28 - 63.85
Shares Outstanding (Mil)490.80

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 5,188 5,446 5,755
EPS ($) 2.32 2.68 3.00
EPS without NRI ($) 2.32 2.68 3.00
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.08%
Dividends per Share ($) 0.41 0.43
» More Articles for ZTS

Headlines

Articles On GuruFocus.com
Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in A Jun 23 2017 
Spark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis a Jun 23 2017 
TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland Jun 23 2017 
Applied Ventures Ramps Investment in Korea with New Innovation Fund Jun 22 2017 
Evolent Health, Inc. Announces Pricing of Secondary Public Offering of Class A Common Stock Jun 22 2017 
SEACOR Marine Announces “Stalking Horse” Bid to Form Joint Venture With Montco Offshore, I Jun 22 2017 
Greenbrier announces webcast and conference call of quarterly financial results Jun 22 2017 
NXT Energy Solutions Announces Results of Annual General Meeting Jun 22 2017 
Motif Bio Announces Result of General Meeting and Total Voting Rights Jun 22 2017 
PNC Releases Results Of Annual Dodd-Frank Company-Run Stress Test Jun 22 2017 

More From Other Websites
Cramer's lightning round: Don't go down the food chain in this space Jun 22 2017
ETFs with exposure to Zoetis, Inc. : June 20, 2017 Jun 20 2017
Zoetis, Inc. :ZTS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017 Jun 19 2017
Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial Jun 15 2017
Zoetis, Inc. : ZTS-US: Dividend Analysis : June 15th, 2017 (record date) : By the numbers : June 15,... Jun 15 2017
Looking For A Better Entry Point, BMO Downgrades Zoetis Shares Jun 13 2017
Zoetis Stock Is Sizzling Hot -- Here's What Could Make It Cool Down Jun 11 2017
Adamas Provides Positive Long-term Data on Parkinson's Drug Jun 09 2017
Zoetis (ZTS) Up 6.4% Since Earnings Report: Can It Continue? Jun 08 2017
Jazz Pharma Sleep Disorder Candidate Positive in Phase III Jun 07 2017
Celgene and Agios Announce Data on Idhifa for Leukemia Jun 07 2017
Zoetis Just Hit an All-Time High: Here's Why the Stock Should Go Higher Jun 03 2017
Celgene & Acceleron Complete Enrollment on Thalassemia Drug Jun 02 2017
Zoetis to Participate in the William Blair Growth Stock Conference Jun 01 2017
Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet May 26 2017
Zoetis to Participate in the Stifel 2017 Dental and Veterinary Conference May 25 2017
Horizon (HZNP) Sells European Rights for Procysbi & Quinsair May 25 2017
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint May 23 2017
Can These 3 High-Flying Healthcare Stocks Reach the Clouds? May 23 2017
Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study May 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}